This content is not available in your region

Bayer in gene therapy collaboration with Mammoth Biosciences

Bayer in gene therapy collaboration with Mammoth Biosciences
Bayer in gene therapy collaboration with Mammoth Biosciences   -   Copyright  Thomson Reuters 2022
By Reuters

By Ludwig Burger and Patricia Weiss

FRANKFURT -Bayer on Monday struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen its cell and gene therapy development efforts.

Unlisted U.S. biotech firm Mammoth will initially receive $40 million from Bayer plus potential milestone payments of more than $1 billion contingent on scientific and commercial achievements.

The initial focus of the collaboration will be liver-based diseases, the companies said in a joint statement on Monday.

Mammoth, headquartered in the San Francisco Bay area, was co-founded by Nobel laureate Jennifer Doudna. She shared the 2020 Nobel Prize in Chemistry with Emmanuelle Charpentier for developing the CRISPR/CAS9 gene editing tool.

Among previous steps to build a cell and gene therapy business, Bayer acquired BlueRock Therapeutics and Asklepios Biopharmaceutical in 2019 and 2020, respectively.

In late 2020, it agreed an alliance on anti-tumour immune cell therapies with Atara Biotherapeutics.